hotspot -WSS

hotspot

author：explore 2025-09-29 12:30:35 - browse：369

A clipboard with checklist on blue dark background. -- health tech coverage from STAT — Adobe

A Pittsburgh artificial intelligence startup emerging as a challenger to Microsoft’s clinical note taking business has raised $150 million, a rare mega deal in a funding lull. The startup, Abridge, also has an unlikely cheerleader: Paul Ricci, the former head of Nuance, the service from Microsoft it competes with.

Abridge sells an AI tool that rapidly transcribes and summarizes doctors’ conversations with patients in a hospital’s electronic health records software. The startup’s leaders and investors tell STAT they’re betting that their medical knowledge, agility, and willingness to co-develop features with customers makes it a more attractive long term option than Nuance, which Microsoft says is currently used by most U.S. hospitals.

Microsoft, Abridge and other startups like Suki, Corti and Nabla are locked in a race to ease provider burnout by automating clinical note taking, and — thanks to generative AI — organizing the data in a way that could improve care, such as suggesting topics for follow-up, simplifying billing or analyzing trends at the broader patient population level.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Microbiome research is starting to find links to chronic diseases

WSS

Extreme heat events are a public health emergency

Medical student insurance fails on mental health care coverage

STAT Executive Editor Rick Berke on STAT's 8th birthday

Diversify hospital leadership teams to protect BIPOC patient health

FDA approves potent Eli Lilly obesity drug, Zepbound

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

explore

hotspot

focus

In age of alternative facts, a scholarly course on calling out crap

MoonLake credibility takes another hit with mid

The high cost of giving birth even with insurance

Just how powerful is the placebo effect?

Medicare proposal to cover medical devices draws a mixed reaction

Lasker Awards 2023: Winners in biomedical research

Psychedelics group wrestles with new pharma identity

Abortion clinic in Cancun will cater to Americans

Apple is now the first public company to be valued at $3 trillion

Changes to biosimilar regulatory framework must prioritize patients

knowledge

HPV cancer vaccine study demonstrates efficacy

Biotech incubator Curie.Bio graduates its first startup

EpiPen alternative approval delay highlights citizen petition issue

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

FDA approves potent Eli Lilly obesity drug, Zepbound

Second xenotransplant done with gene

focus

hotspot

Wikipedia

explore